Pharma Q3 preview: India growth, base business may offset US headwinds
Apart from the Revlimid loss, generic price competition in the US, and the addition of new medical representatives in the India business are likely to impact margins this quarter.
Apart from the Revlimid loss, generic price competition in the US, and the addition of new medical representatives in the India business are likely to impact margins this quarter.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
